Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER GRAHAM ROSE

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1972530293
CMS profile
271117
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,619.87

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,445.00 1
Food and Beverage $174.87 4

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $2,509.00 2
Merck Sharp & Dohme LLC $42.58 1
GlaxoSmithKline, LLC. $39.99 1
Medtronic, Inc. $28.30 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER GRAHAM ROSE

NPI 1972530293 · CMS profile ID 271117

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972530293?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER GRAHAM ROSE, NPI 1972530293, CMS profile ID 271117. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972530293?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PETER GRAHAM ROSE, NPI 1972530293, CMS profile ID 271117. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972530293?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PETER GRAHAM ROSE, NPI 1972530293, CMS profile ID 271117, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1972530293?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $2,619.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $28.3009/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119573111 CMS
Eisai Inc. $2,445.0004/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110773019 CMS
Eisai Inc. $64.0003/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110773021 CMS
Merck Sharp & Dohme LLC $42.5803/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141586736 CMS
GlaxoSmithKline, LLC. $39.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116731298 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $409.23 5
PY2020 $11.17 1
PY2021 $253.76 3
PY2022 $97.13 2
PY2023 $243.38 4
PY2024 $2,619.87 5
PY2025 $120.53 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,915.82 36
PY2024 Principal investigator $122,555.68 90
PY2023 Principal investigator $83,530.41 18
PY2022 Principal investigator $185,097.72 27
PY2021 Principal investigator $115,797.72 18
PY2020 Principal investigator $248,307.25 23
PY2019 Principal investigator $509,138.01 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $506.63 12/31/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Partial Response Following First Line Platinum Based Chemotherapy No dispute reported 06/30/2026 736749479
Principal investigator 1 Merck Sharp & Dohme Corporation $340.31 12/15/2020 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740766131
Principal investigator 1 Seagen Inc. $19,580.28 10/30/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 733453619
Principal investigator 1 Clovis Oncology, Inc. $16,615.00 10/26/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177273
Principal investigator 1 Genentech, Inc. $1,682.00 10/21/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 742997045
Principal investigator 1 Merck Sharp & Dohme Corporation $340.31 10/13/2020 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740766129
Principal investigator 1 Genentech, Inc. $2,523.00 09/01/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 742997055
Principal investigator 1 Merck Sharp & Dohme Corporation $340.31 08/11/2020 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740766133
Principal investigator 1 Clovis Oncology, Inc. $9,966.25 08/10/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177271
Principal investigator 1 PFIZER INC. $1,586.00 08/06/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3 MULTICENTER RANDOMIZED OPENLABEL STUDY OF AVELUMAB MSB0010718C ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUMRESISTANTREFRACTORY OVARIAN CANCER No dispute reported 06/30/2026 742929569
Principal investigator 1 PFIZER INC. $60,972.60 08/06/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3 MULTICENTER RANDOMIZED OPENLABEL STUDY OF AVELUMAB MSB0010718C ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUMRESISTANTREFRACTORY OVARIAN CANCER No dispute reported 06/30/2026 742929573
Principal investigator 1 Seagen Inc. $1,991.43 07/28/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 733453589
Principal investigator 1 Clovis Oncology, Inc. $63,750.00 07/13/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177269
Principal investigator 1 Seagen Inc. $3,856.52 07/13/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 733453587
Principal investigator 1 Seagen Inc. $6,777.50 07/07/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 733453585
Principal investigator 1 Merck Sharp & Dohme Corporation $268.47 06/09/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740789887
Principal investigator 1 Clovis Oncology, Inc. $39,141.25 06/08/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177267
Principal investigator 1 Seagen Inc. $8,588.40 06/01/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 733453583
Principal investigator 1 Merck Sharp & Dohme Corporation $214.77 05/28/2020 Covered Recipient Teaching Hospital
Hillcrest Hospital
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740789931
Principal investigator 1 Merck Sharp & Dohme Corporation $214.77 05/28/2020 Non-covered Recipient Entity
MOLL CANCER CENTER
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740789977
Principal investigator 1 Seagen Inc. $869.38 04/28/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 733453581
Principal investigator 1 Merck Sharp & Dohme Corporation $268.47 04/01/2020 Covered Recipient Teaching Hospital
Hillcrest Hospital
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 740789933
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,913.60 01/30/2020 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Partial Response Following First Line Platinum Based Chemotherapy No dispute reported 06/30/2026 736741179